Drug Trial Radar · NCT05631795
Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment
Last checked: Nov 20, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Aug 9, 2022
Primary completion
Jun 12, 2025
Study completion Jun 12, 2025
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine the safety of alpelisib plus fulvestrant in men and post-menopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced or metastatic breast cancer (aBC) with a PIK3CA mutation, whose disease had progressed on or after endocrine-based treatment.
Conditions
- Advanced Breast Cancer
Interventions
AlpelisibDrug
Film coated tablet for oral use. Participants will be treated with 300 mg of alpelisib once daily starting on Cycle 1 Day 1
FulvestrantDrug
Injection for intramuscular administration. Participants will be treated with fulvestrant 500 mg on Cycle 1 Day 1 and Day 15, and Day 1 of every cycle thereafter in a 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With at Least One On-treatment Adverse Events (AEs)Time frame: From start of treatment up to 30 days after last dose of study treatment, assessed up to approximately 7 months
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Ahmedabad, India
Novartis Investigative Site
Kolkata, India
Novartis Investigative Site
Guwahati, Assam, India
Novartis Investigative Site
Surat, Gujarat, India
Novartis Investigative Site
Thalassery, Kerala, India
Novartis Investigative Site
Trivandrum, Kerala, India
Novartis Investigative Site
Bhopal, Madhya Pradesh, India
Novartis Investigative Site
Mumbai, Maharashtra, India
Novartis Investigative Site
Nagpur, Maharashtra, India
Novartis Investigative Site
Pune, Maharashtra, India
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, India
Novartis Investigative Site
Hyderabad, Telangana, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.